Artificial intelligence tools based on large language models (LLMs) find it hard to identify genetic conditions based on patient-written descriptions, suggesting there is some way to go bef
Canada's Firefly Neuroscience has completed a listing on the Nasdaq via a $45 million reverse merger with IT group WaveDancer, opening up new financing routes for its artificial intelligenc
An FDA-approved digital therapeutic (DTx) that can be used to help people living with major depressive disorder (MDD) has been launched in the US and is available in mobile app stores.
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued
Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.